Shares of Moderna plunged 25% on Thursday following a potential leak of Phase 3 clinical trial data for its experimental cancer vaccine, setting off a sharp selloff that comes after Citigroup downgraded Moderna and said its initial positive vaccine results gave it an “unjustifiable” valuation.
